Solésence Reports Third Quarter 2025 Financial Results

Rhea-AI Summary

Solésence (Nasdaq: SLSN) reported third quarter 2025 results for the period ended September 30, 2025, highlighting an ongoing strategic transformation with executive promotions and operational consolidation.

Key financials: Revenue $14.5M vs $16.9M a year earlier; Gross margin 23% vs 36% prior year; Gross profit $3.4M vs $6.1M; Net loss $1.1M vs net income $3.0M. Operational moves include consolidating manufacturing from three facilities to two, increased automation, and a unified R&D/product/quality group. Company appointed Kevin Cureton as CEO, Laura Riffner as CFO, and Yoana Dvorzsak to lead innovation and product integrity. A conference call was scheduled for Nov 11, 2025 at 8:30 a.m. ET.

Positive

• Manufacturing consolidated from 3 to 2 facilities
• Automation improvements implemented to streamline manufacturing
• Unified R&D and Quality into a single Innovation and Product Integrity group
• Leadership appointments: Kevin Cureton CEO and Laura Riffner CFO

Negative

• Revenue declined to $14.5M from $16.9M (≈14.2% drop)
• Gross margin fell to 23% from 36% (13 percentage-point decline)
• Net result swung to a $1.1M loss from $3.0M income (≈$4.1M swing)
• Gross profit decreased to $3.4M from $6.1M

Insights

Corporate Finance Strategist

Results show clear near-term deterioration: lower revenue, compressed margins and a swing to loss raise material short-term concerns.

Solésence reported third quarter revenue of $14.5 million, down from $16.9 million year-over-year, with gross profit of $3.4 million and gross margin falling to 23% from 36%. The company recorded a net loss of $1.1 million versus net income of $3.0 million in the prior-year quarter. Those three metrics—top line, margin, and bottom line—all moved unfavorably in the same period, which is a concrete signal of weaker operating performance.

The business mechanism described focuses on operational consolidation and automation, and leadership changes aimed at restoring profitability. Those actions can reduce costs and improve product integrity, but their impact is execution-dependent and typically realized over multiple quarters. The press release provides no quantified near-term savings or timeline for margin recovery, so the announcement does not resolve the current revenue and margin shortfalls.

Watch for specific, monitorable milestones over the next few quarters: reported cost savings from the manufacturing consolidation, quarter-over-quarter gross margin improvement, and return to positive net income by Q1 2026 or later. Also note the company will discuss results on a conference call on November 11, 2025, which may provide additional detail on expected timing and quantified targets.

Advances Strategic Transformation with Key Changes in Executive Leadership, Product Development and Operations

ROMEOVILLE, Ill., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the third quarter ended September 30, 2025.

Recent Highlights and Accomplishments

• Continued strategic transformation to drive future innovation and growth with promotion of Kevin Cureton to President and Chief Executive Officer.
• Appointed Laura Riffner, a seasoned financial and operations expert, as Chief Financial Officer to lead accounting and finance management and support strategic planning.
• Yoana Dvorzsak to lead newly unified group that combines Solésence’s research and development, product and component development, regulatory and quality operations as Vice President, Innovation and Product Integrity.
  
  

“As part of our ongoing transformation, Solésence implemented several strategic initiatives driving improvements in innovation, product quality and operational efficiency,” said Kevin Cureton, President and Chief Executive Officer. “At the same time, we are dedicated to expanding the reach of our skin care, sun care and color cosmetic solutions to consumers who are passionate for our products. Despite a challenging third quarter, we are confident that our wider organizational and commercial strategies will solidify Solésence’s future as a dynamic, highly profitable growth company.”

Third Quarter 2025 Financial Results

• Revenue for the third quarter was $14.5 million, compared to $16.9 million for the same period in 2024.
• Gross margin in the third quarter was 23%, compared to 36% for the same period in 2024.
• Gross profit in the third quarter was $3.4 million, compared to $6.1 million for the same period in 2024.
• Net loss for the third quarter was $1.1 million, compared to net income of $3.0 million for the same period in 2024.
  
  

Third Quarter 2025 Operational Highlights

• Unified operations group and executed on structural changes to drive operational efficiencies across manufacturing and supply chain.
• Consolidated the Company’s manufacturing facilities to two from three.
• Improved automation to streamline manufacturing processes.
  
  

“Our recent structural changes focused on streamlining operations, enhancing product integrity, and improving productivity have strategically positioned Solésence for scaled growth,” said Laura Riffer, Chief Financial Officer of Solésence. “We reorganized vital parts of the business—specifically unifying our R&D and Quality teams, consolidating manufacturing, and increasing production automation. The culmination of all these efforts will provide the sound operational foundation necessary to efficiently deliver the highest quality products to our brand partners, solidifying our position with them as their long-term partner of choice.”

Conference Call

Solésence will host its third quarter conference call on Tuesday, November 11, 2025, at 7:30 a.m. CT, 8:30 a.m. ET, to discuss its financial results and provide a business and financial update. On the call will be Kevin Cureton, President and Chief Executive Officer, Laura Riffner, Chief Financial Officer, and Jess Jankowski, Board Advisor.

Webcast Link: https://edge.media-server.com/mmc/p/qur8mp24  

Dial-In Link: https://register-conf.media-server.com/register/BI2e27b8a6c7664f28b7a16148b68f01ba  

To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the option to have the system dial-out to you once the conference call begins. If you forget your PIN prior to the conference call, you can simply re-register.

The call may also be accessed through the Company’s investor relations website, at https://ir.solesence.com/. Please join the conference call at least five minutes before prior to the start time.

FINANCIAL RESULTS AND NON-GAAP INFORMATION

Use of Non-GAAP Financial Information

Solésence believes that the presentation of results excluding certain items, such as non-cash equity compensation charges, provides meaningful supplemental information to both management and investors, facilitating the evaluation of performance across reporting periods. The Company uses these non-GAAP measures for internal planning and reporting purposes. These non-GAAP measures are not in accordance with, or an alternative for, Generally Accepted Accounting Principles (“GAAP”) and may be different from non-GAAP measures used by other companies. The presentation of this additional information is not meant to be considered in isolation or as a substitute for net income or net income per share prepared in accordance with GAAP.

About Solésence, Inc.

Solésence, Inc. (Nasdaq: SLSN), is a leader in scientifically-driven health care solutions across beauty and life science categories. With a mission to deliver joy through innovation, inclusivity and the science of beautiful skin, we have redefined mineral-based sun protection by maximizing transparency, effectiveness, aesthetics, and wearability — empowering individuals to embrace beauty on their own terms. Combining best-in-class skin health solutions with the celebration of self-care, we allow brands to deliver unique product claims and attributes by seamlessly integrating protection, prevention, and treatment technologies into daily use products. Learn more at solesence.com.

Forward-Looking Statements

This press release contains words such as “expects,” “shall,” “will,” “believes,” and similar expressions that are intended to identify forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements in this announcement are made based on the Company’s current beliefs, known events and circumstances at the time of publication, and as such, are subject in the future to unforeseen risks and uncertainties that could cause the Company’s results of operations, performance, and achievements to differ materially from current expectations expressed in, or implied by, these forward-looking statements. These risks and uncertainties include, without limitation, the following: a decision by a customer to cancel a purchase order or supply agreement in light of the Company’s dependence on a limited number of key customers; uncertain demand for, and acceptance of, the Company’s engineered materials, ingredients, and fully formulated products; the Company’s manufacturing capacity and product mix flexibility in light of customer demand; the Company’s limited marketing experience; changes in development and distribution relationships; the impact of competitive products and technologies; the Company’s dependence on patents and protection of proprietary information; the resolution of litigation in which the Company may become involved; the impact of any potential new government regulations that could be difficult to respond to or too costly to comply with while remaining financially viable; the ability of the Company to maintain an appropriate electronic trading venue; and other factors described in the Company’s Form 10-K filed March 31, 2025. In addition, the Company’s forward-looking statements could be affected by general industry and market conditions and growth rates. Except as required by federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties, or other contingencies.  

Media Contact:
media@solesence.com

Investor Relations Contact:
investors@solesence.com

SOLESENCE, INC
CONSOLIDATED BALANCE SHEETS
(Unaudited Consolidated Condensed)
		(in thousands except share and per share data)
		September 30,				December 31,
			2025				2024
ASSETS		(Unaudited)
Current assets:
Cash		$	429			$	1,409
Trade accounts receivable			11,438				5,655
Allowance for credit losses			(1,729	)			(786	)
Trade accounts receivable, net			9,709				4,869
Inventories, net			18,869				20,267
Prepaid expenses and other current assets			3,785				2,803
Total current assets			32,792				29,348
Equipment and leasehold improvements, net			13,938				12,734
Operating leases, right of use			7,257				7,917
Other assets, net			-				3
Total assets		$	53,987			$	50,002
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Line of credit, accounts receivable, related party		$	5,316			$	-
Current portion of line of credit, inventory, related party			-				4,000
Current portion of debt, related parties			-				1,000
Current portion of operating lease obligations			1,224				1,260
Accounts payable			4,826				9,093
Deferred revenue			1,197				5,571
Accrued expenses			5,301				4,849
Total current liabilities			17,864				25,773
Long-term portion of operating lease obligations			8,144				9,037
Long-term portion of line of credit, inventory, related party			9,500				-
Long-term portion of debt, related parties			1,000				-
Asset retirement obligations			252				246
Total long-term liabilities			18,896				9,283
Contingent liabilities
Stockholders' equity:
Preferred stock, $.01 par value, 24,088 shares authorized and
no shares issued and outstanding			-				-
Common stock, $.01 par value, 95,000,000 shares authorized;
70,536,845 and 70,103,279 shares issued and outstanding on
September 30, 2025 and December 31, 2024, respectively			705				700
Additional paid-in capital			115,323				114,674
Accumulated deficit			(98,801	)			(100,428	)
Total stockholders' equity			17,227				14,946
Total liabilities and shareholders' equity		$	53,987			$	50,002

SOLESENCE, INC
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited Consolidated Condensed)
(in thousands except share and per share data)
					Three months ended							Nine months ended
					September 30,							September 30,
						2025				2024			2025			2024
Revenue:
	Product revenue				$	14,533			$	16,785		$	49,369		$	39,479
	Other revenue					64				81			212			301
		Net revenue				14,597				16,866			49,581			39,780
	Cost of revenue					11,227				10,764			36,952			26,358
		Gross profit				3,370				6,102			12,629			13,422
Operating expense:
	Research and development expense					1,082				970			3,055			2,746
	Selling, general and administrative expense					3,069				1,934			8,188			5,321
Income (loss) from operations						(781	)			3,198			1,386			5,355
	Interest expense					339				153			603			562
	Other income, net					-				-			1,234			-
Income (loss) before provision for income taxes						(1,120	)			3,045			2,017			4,793
Provision for income taxes						-				-			390			-
Net income (loss)					$	(1,120	)		$	3,045		$	1,627		$	4,793
Net income (loss) per share-basic					$	(0.02	)		$	0.04		$	0.02		$	0.08
Weighted average number of common shares outstanding - basic						70,500,925				69,873,394			70,269,539			59,778,119
Net income (loss) per share-diluted					$	(0.02	)		$	0.04		$	0.02		$	0.08
Weighted average number of common shares outstanding - diluted						70,500,925				71,935,394			72,745,662			61,725,119

SOLESENCE, INC
CONSOLIDATED STATEMENTS OF OPERATIONS - EXPANDED SCHEDULE
(Unaudited Consolidated Condensed)
(in thousands except share and per share data)
					Three months ended							Nine months ended
					September 30,							September 30,
						2025				2024			2025			2024
Revenue:
	Product revenue				$	14,533			$	16,785		$	49,369		$	39,479
	Other revenue					64				81			212			301
		Net revenue				14,597				16,866			49,581			39,780
	Cost of revenue detail:
	Depreciation					216				219			649			663
	Non-Cash equity compensation					19				26			73			80
	Other costs of revenue					10,992				10,519			36,230			25,615
		Cost of revenue				11,227				10,764			36,952			26,358
			Gross profit			3,370				6,102			12,629			13,422
Operating expense:
	Research and development expense detail:
	Depreciation					4				6			11			17
	Non-Cash equity compensation					41				34			96			99
	Other research and development expense					1,037				930			2,948			2,630
		Research and development expense				1,082				970			3,055			2,746
	Selling, general and administrative expense detail:
	Depreciation and amortization					5				6			17			20
	Non-Cash equity compensation					61				100			199			298
	Other selling, general and administrative expense					3,003				1,828			7,972			5,003
		Selling, general and administrative expense				3,069				1,934			8,188			5,321
Income from operations						(781	)			3,198			1,386			5,355
	Interest expense					339				153			603			562
	Other income, net					-				-			1,234			-
Income before provision for income taxes						(1,120	)			3,045			2,017			4,793
Provision for income taxes						-				-			390			-
Net income (loss)					$	(1,120	)		$	3,045		$	1,627		$	4,793
Non-GAAP Disclosure (see note regarding Non-GAAP disclosures):
	Addback Interest, net					339				153			603			562
	Addback Depreciation/Amortization					225				231			677			700
	Addback Non-Cash Equity Compensation					121				160			368			477
	Subtract Non-Cash Other Income					-				-			-			-
	Adjusted EBITDA				$	(435	)		$	3,589		$	3,275		$	6,532

FAQ

What were Solésence (SLSN) Q3 2025 revenue and net income figures?

Q3 2025 revenue was $14.5M and the company reported a $1.1M net loss for the quarter.

Why did Solésence (SLSN) gross margin fall in Q3 2025?

The company reported gross margin of 23% in Q3 2025 versus 36% a year earlier; the release cites operational restructuring and cost dynamics as context.

How will Solésence's (SLSN) manufacturing consolidation impact operations?

Solésence consolidated manufacturing from three facilities to two and increased automation to improve efficiency and product quality.

What leadership changes did Solésence (SLSN) announce on Nov 11, 2025?

Kevin Cureton was promoted to President and CEO, Laura Riffner named CFO, and Yoana Dvorzsak will lead the unified innovation/product integrity group.

When and how can investors join Solésence (SLSN) Q3 2025 earnings call?

The conference call was scheduled for Nov 11, 2025 at 8:30 a.m. ET; a live webcast and dial-in registration link were provided on the investor relations site.

Did Solésence (SLSN) provide non-GAAP disclosures with the Q3 2025 results?

Yes. The company noted use of non-GAAP measures excluding items like non-cash equity compensation for supplemental analysis.